JNJ-7706621 , 98% , 443797-96-4

Synonym(s):
4-(5-Amino-1-(2,6-difluorobenzoyl)-1H-[1,2,4]triazol-3-ylamino)-benzenesulfonamide, JNJ-7706621, Aurora Kinase Inhibitor I;Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem

CAS NO.：443797-96-4

Empirical Formula: C15H12F2N6O3S

Molecular Weight: 394.36

MDL number: MFCD11100270

PRODUCT Properties

• Melting point: 149-155℃
• Boiling point: 676.6±65.0 °C(Predicted)
• Density: 1.71
• storage temp.: +2C to +8C
• solubility: Soluble in DMSO at 15mg/ml
• form: White solid
• pka: 9.80±0.12(Predicted)
• color: White to off-white
• Sensitive: Light Sensitive

Description and Uses

JNJ-7706621 is a dual inhibitor of cyclin-dependent kinases (CDKs) and Aurora kinases. It potently inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk3/cyclin E, Cdk4/cyclin D1, Cdk6/cyclin D1, Aurora A, and Aurora B in vitro (IC₅₀s = 9, 4, 3, 58, 253, 175, 11, and 15 nM, respectively). It shows selectivity for these enzymes over a panel of other receptors and kinases, although it exhibits submicromolar inhibition of VEGF and FGF receptors, as well as GSK3β. JNJ-7706621 blocks the growth of a large variety of cancer cell lines (IC₅₀ values range from 112 to 514 nM), with lower potency against normal cells (IC₅₀ values between 3.67 and 5.42 μM). It induces the regression of A375 melanoma human tumor xenografts in mice. JNJ-7706621 is a substrate for the ATP-binding cassette transporter G2, also known as breast cancer resistance protein.

JNJ-770662 is a broad spectrum inhibitor of cyclin-dependent kinases and aurora kinases including CDK1/Cyclin B, CDK2/Cyclin A, CDK2/Cyclin E, Aurora-A and Aurora-B. JNJ-770662 has been shown to induce growth suppression and mitotic defects, these results suggest that JNJ-7706621 could be useful for cell cycle analysis and therapy of various cancers, including Ewing''s sarcoma.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H335
• Precautionary statements: P261-P280a-P304+P340-P305+P351+P338-P405-P501a